Carb-X

ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
2018-09-04 08:00 - 2018-09-07 17:00 UTC | Intercontinental Lisbon, R. Castilho 149, Lisbon, 1099-024, Portugal
Drug development for AMR is a rapidly moving field. The stakes are high. A difficult riskbenefit balance must be struck. There are relatively few new classes of antibiotics and each requires highly skilled and experienced investigators to ensure these compounds reach patients. This meeting is the forum where those issues are discussed and debated.

Vaccines Against Clostridium difficile Infection (CDI): A Roadmap for the Future
2018-09-05 08:00 - 17:00 (America/New_York) | NIAID Conference Center, 5601 Fishers Lane, Rockville, MD, United States
There are 453K new C. difficile infections (CDI) every year and 83K recurrent infections, yet there are no licensed vaccines against this important nosocomial pathogen. The current pipeline of clinical-stage vaccines consists of two toxin-based candidates and one phase 3 candidate, which is no longer being pursued. Although mathematical studies and computer-simulation models suggest that a CDI vaccine would be a cost-effective approach to protect against disease, the overall public health impact for a CDI vaccine remains unclear. Moreover, there are gaps in our understanding of the mucosal immune responses against CDI and how immunity against nontoxin antigens can improve protection. This timely workshop will explore and identify high-priority knowledge gaps in C. difficile pathogenesis and immunology in order to establish a path for future CDI vaccine development, while considering the public health impact of introducing a licensed vaccine based on anti-toxin immunity.

Antibacterial drugs: Clinical development for non-developers Webinar
2018-09-11 11:00 - 12:00 (America/New_York) | Webinar
Part 2: Development of antibacterial drugs targeting specific pathogens
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B), best suited for more broad-spectrum products, where the risks are lower. In this webinar, we will discuss the development of products that target a single species of bacteria where the risks may be higher. While development of therapies for infections caused by a single bacterial species that is identified relatively frequently at a given body site of infection (e.g. Staphylococcus aureus (or even MRSA) in acute bacterial skin and skin structure infections) makes for readily feasible trials, this is not the case for infrequently occurring infections such as those caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Under these circumstances, a clinical development program can be very challenging. This webinar will give an overview of the practical challenges associated with developing a therapy for a low frequency event for which treatment must be initiated urgently. The presentation will be followed by an interactive Q&A session.

FDA Commissioner Unveils Plan to Combat Antibiotic Resistance - Live Webcast
2018-09-14 10:00 - 11:30 (America/New_York)
At least 2 million Americans a year contract an antibiotic-resistant infection, the Centers for Disease Control and Prevention reports. So, what can the U.S. do to safeguard public health amid the growing threat of these superbugs?
Tune in to a live webcast as Dr. Scott Gottlieb, commissioner of the U.S. Food and Drug Administration, announces the agency’s plans to combat antibiotic resistance.
Following Gottlieb’s remarks, a panel of FDA senior officials will discuss aspects of the plan in more detail and take questions from the audience.

The AMR Challenge Launch Event
2018-09-25 18:00 - 21:00 (America/New_York) | The Roosevelt Hotel, 45 E 45th St, New York City, NY, 10017, United States
The AMR Challenge encourages global leaders to make formal commitments that further progress against antimicrobial resistance. Your efforts could contribute to solutions that protect humans, animals, and the environment from this global threat.
The first batch of commitments will be unveiled at a United Nations (UN) General Assembly side event on September 25, and will commence a “commitment year” that invites organizations worldwide to participate.
Attendees include Alison Haight, CARB-X Director of Finance

Antibacterial Discovery and Development Summit
2018-09-26 - 2018-09-27 | Sheraton Boston, 39 Dalton Street, Boston, MA, 02199, United States
Helping Antibacterial Development to Move Forward – New discovery platforms, novel screens and approaches are vital for the discovery of new antibacterials and for ceasing the dangerous trend of multidrug microbial resistance. Cambridge Healthtech Institute’s 5th Annual Antibacterial Discovery and Development track will focus on the general, strategic issues and solutions that would allow new antibacterial development to move forward. The conference will be held as part of the 5th Annual Re-Entering Antibacterial Discovery and Development Summit, and it will be followed by Targeting Gram-Negative Pathogens.
Kevin Outterson, Executive Director of CARB-X to speak about funding opportunities with CARB-X on September 27th at 8:25am and join the panel discussion at 10:20am.
Mark Albrecht of BARDA to speak on how BARDA is addressing the global threat of antimicrobial resistance on September 27th at 8:45am.

Grand Challenges Annual Meeting 2018
2018-10-15 - 2018-10-18 | Estrel Hotel, Sonnenallee 225, 12057 Berlin, Germany
The Grand Challenges Annual Meeting aims to accelerate the translation of innovation to impact to address the world’s most urgent global health and development problems. The meeting is a forum for researchers to share their work, learn about cutting-edge advances in the field and build collaborations with other investigators and organizations. This year the meeting will partially overlap with the 10th World Health Summit.
Hosted by the German Federal Ministry of Education & Research, Bill & Melinda Gates Foundation, Grand Challenges Canada, United States Agency for International Development, and Wellcome.
Invitation Only

Fostering Investment in the Development of New Antibacterial Treatments - UNCTAD World Investment Forum
2018-10-23 14:30 - 17:30 (America/New_York) | Palais des Nations in Geneva, 1211, Geneva, Switzerland
Antimicrobial resistant infections (AMR) are on the rise and pose a significant global risk. Developing countries, in particular, are vulnerable because they often lack key medical resources. The development of new antibacterial treatments is costly while the return on investment is low. Organized in cooperation with the World Health Organization (WHO), the conference will explore solutions to this dilemma, seeking to facilitate cooperation between biotech firms, potential investors and governments for AMR investment.

World Anti-Microbial Resistance Congress 2018
2018-10-25 - 2018-10-26 | Rits Carlton, 1150 22nd St NW, Washington, DC, 20037, United States
At the 4th Annual World Anti-Microbial Resistance Congress, over 400 stakeholders will gather in Washington D.C. to discuss critical challenges and opportunities to advance antibiotic and diagnostics development, improve antimicrobial stewardship practice and incentivize funding and partnering to bring innovation to patients and the healthcare system in need. Discussions will be addressing 4 key areas: Antibiotic R&D, Diagnostics, Antimicrobial Stewardship, and Innovation Showcase.
Presentations by Tyler Merkeley of BARDA and Dr. Barry Eisenstein, Chair of the CARB-X Advisory Board.

BARDA Industry Day
2018-10-29 - 2018-10-30 | Grand Hyatt Washington, 1000 H St NW, Washington, DC, 20001, United States
The Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response (ASPR), invites you to participate in our annual conference at which you can learn about U.S. Government medical countermeasure priorities, interact with BARDA and ASPR staff, and network with public and private sector colleagues working in this space.
This year’s theme focuses on the importance of innovation and collaboration.

2018 BioInfect Conference
2018-11-08 08:00 - 17:00 (Europe/London) | Alderley Park Conference Centre, Alderly Park, Cheshire, SK10 4TG, United Kingdom
Antimicrobial resistance is an increasingly serious threat to global public health that requires action across all government sectors and society. BioInfect will look at the critical issues relating to the development of new anti-infectives and the endemic problem of resistance.

Dr. Richard Lawson, CARB-X Senior Project Manager, will be delivering the keynote address.

Lecture by Kevin Outterson: Why is a lawyer leading antibiotic R&D at CARB-X?
2018-11-12 00:30 - 13:30 (Europe/London) | Wellcome Trust, Euston Road, London, NW1, United Kingdom
Kevin Outterson is the N Neal Pike Professor of Health and Disability Law at Boston University and the Executive Director of CARB-X, the world’s largest product development partnership addressing drug-resistant bacterial infections. He will share his personal stories of how experiences, skills, passion and faith converge in the efforts to protect us all from drug-resistant bacterial infections.

All-Party Parliamentary Group on Antibiotics: How close are we to meeting the urgent need for new antibiotics?
2018-11-13 15:00 - 17:00 (Europe/London) | 1 Parliament Street, 1 Parliament Street, London, A3212,, United Kingdom
The All-Party Parliamentary Group on Antibiotics APPG-A exists to raise the profile of antibiotic resistance, the need to preserve antibiotics through education on their appropriate use including non‐human uses, the lack of new treatments for bacterial infections and to help accelerate efforts to discover, research and develop new treatments.
The British Society for Antimicrobial Chemotherapy serves as Secretariat to the APPG-A.
This meeting will focus on the work of partnership bodies like CARB-X and the Global Antibiotic Research & Development Partnership (GARDP) in relation to antibiotic development, pipeline coordination, and the legacy of the DRIVE-AB initiative.
Speakers include Kevin Outterson, Executive Director of CARB-X

GARDP Webinar: Making Safety a Part of Drug Design
2018-11-13 17:00 (Europe/Berlin) | Webinar
This webinar aims at making a presentation of a recent GARDP co-organized conference session accessible to anyone who didn’t have the chance to attend the meeting.
After the showing of the recording of her presentation “Making Safety a Part of Drug Design”, Claire Sadler will join us online for a live Q&A session. This presentation was part of the GARDP and CARB-X co-organized “Antibiotic Bootcamp for Developers: Preclinical Toxicology” at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance in Lisbon in September 2018.
Speaker: Claire Sadler
Moderator: Ursula Theuretzbacher
Host: François Franceschi
Please click here to register.

Max Planck Institute for Innovation and Competition Conference
2018-11-16 | Berlin, Berlin, Germany
Additional details to follow.

Presentation by Kevin Outterson, Executive Director of CARB-X.

Call to Action on Antimicrobial Resistance
2018-11-19 08:00 - 2018-11-20 17:00 (Africa/Accra) | Accra, Ghana, Accra, Ghana
Wellcome Trust is to co-host a second global conference to help drive pioneering action to stop the rise and spread of superbugs. The two-day Call to Action, taking place in Accra this November, is co-hosted with the governments of Ghana and Thailand, and the United Nations Foundation, and is organized in partnership with the Inter-Agency Coordination Group (IACG) on Antimicrobial Resistance.
Health representatives from national governments and agencies, civil society, the private sector and global philanthropies will be invited to come together at the Call to Action to focus on how to address the most critical gaps in tackling the development and spread of drug-resistant infections.
Invitation Only
Attendees include Kevin Outterson, Executive Director of CARB-X.

Call to Action Side Event: Access and stewardship plans during antibiotic research and development
2018-11-20 07:30 - 08:45 (America/New_York) | Accra, Ghana, Accra, Ghana
This event is an invitation-only side event to the 2nd Call to Action on Antimicrobial Resistance hosted by the Access to Medicine Foundation, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research & Development Partnership (GARDP). In this session, the Access to Medicine Foundation, CARB-X and GARDP will share how they guide, support and partner with pharmaceutical companies to achieve access and stewardship goals. Presentations will be followed by an open discussion related to the role of different sectors in improving access and stewardship strategies during the R&D process.

6th annual meeting of the Boston Area Antibiotic Resistance Network
2018-12-07 08:30 - 19:00 (America/New_York) | Starr Center for Conferences, 185 Cambridge St., Boston, MA, 02114, United States
Speakers include Karen Gallant, Global Program Director of CARB-X.

CARB-X: Combating Antibiotic Resistance Globally
2019-01-15 12:00 - 13:00 (America/New_York)
With Kevin Outterson. A Boston University Alumni Association special webinar event for BU alumni, but all are welcome to join. Register online

ECRAID-Plan Kick-off meeting
2019-01-17 | Brussels, Belgium, Brussels, Belgium
The European Clinical Research Alliance on Infectious Diseases (ECRAID) focuses on two major challenges: emerging infectious diseases (EID) with epidemic or pandemic potential, caused by new or re-emerging pathogens, and antimicrobial resistance (AMR). This meeting aims to bring together the ECRAID-Plan Project Consortium, Working Group, and key stakeholders to constructively discuss ECRAID and its sustainable solutions to protect Europe, and beyond, from AMR and EID threats over the long-term. This is a closed meeting.
Kevin Outterson, Executive Director of CARB-X, will be on the stakeholder advisory panel. Keynote speakers include EU Commissioner for Research, Science and Innovation, Carlos Moedas, and Wellcome Trust Director, Jeremy Farrar.

REVIVE Webinar: Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
2019-01-29 11:00 - 12:30 (America/New_York) | WEBINAR, Webinar, Webinar, United States
On the 29th of January 2019, Ian Friedland, Sumathi Nambiar, Mair Powell, and David Shlaes will join us for a live webinar about antibacterial drug enhancer combinations and non-traditional products. Following their short presentations, the speakers will be available on the line to respond to your questions.

Hamied Foundation UK-India Antimicrobial Resistance Meeting 2019
2019-02-04 - 2019-02-05 | The Hallam Conference Centre, 44 Hallam Street, London, United Kingdom
The meeting is being organised as part of a programme of work to strengthen the research links between the UK and India with the specific aim of jointly addressing the challenge of AMR.

Webinar - NIAID Resources to Facilitate Discovery & Development of Anti-Infectives
2019-02-21 17:00 - 18:30 (Europe/Paris) | Webinar, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Ann Eakin, Senior Scientific Officer Office of Biodefense, Research Resources & Translational Research, DMID/NIAID/NIH, member of the CARB-X Joint Oversight Committee.
In this presentation, Ann Eakin (US National Institute of Allergy and Infectious Diseases, NIAID) will provide an overview of the various mechanisms of support offered by NIAID to facilitate the discovery and development of drugs, vaccines and diagnostics targeting infectious diseases. The types of support that will be discussed are grants and contracts, as well as preclinical and clinical research services that aim to reduce risk and advance product development efforts. Researchers from any country and from any type of institution (academia, industry, non-profit) are eligible to apply for nearly all types of support mechanisms offered by NIAID, irrespective of prior or current NIH funding.
Ann’s presentation will be complemented by a short presentation of Dan Pevear, Founder and Senior Vice President, Biology and Grants Development, VenatoRx Pharmaceuticals, in which he will share VenatoRx’ experience with NIAID support mechanisms.
The presentations will be followed by a Q&A session.

US FDA Regulatory Approval Process for Anti-microbials Workshhop
2019-03-06 | C-CAMP, Chausa, Bengaluru, India
Workshop hosted by the Centre for Cellular And Molecular Platforms (C-CAMP), a member of the CARB-X Accelerator Network.

The 12th Berlin Conference on Life Sciences - Novel Antimicrobials and AMR Diagnostics 2019
2019-03-14 - 2019-03-15 | Radisson Blu Hotel, Karl-Liebknecht-Strasse 3, Berlin, 10178, Germany
Speakers include Kevin Outterson, CARB-X Executive Director.
The Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.

BSAC Spring Conference 2019
2019-03-21 - 2019-03-22 | International Convention Center, 8 Centenary Square, Birmingham, B1 2EA, United Kingdom
Global views, local problems: Innovative solutions to AMR and infection challenges.
The British Society for Antimicrobial Chemotherapy (BSAC) 2019 Spring Conference offers a state of the art overview of the infection management and antimicrobial resistance landscape. The programme includes keynote lectures, plenary and parallel sessions, debates and an opening series of spotlight presentations – offering insights into the latest in drug discovery and development, socio-economic challenges, new and emerging treatments and diagnostics and debates and challenges policies and usage of antibiotic regimens. Globally focused and locally relevant, the conference brings together key opinion leaders, researchers and clinicians from across Europe and further afield. Alongside the networking and exhibition areas, this event offers outstanding opportunities for education and engagement to all delegates.

Longitude Prize AMR Diagnostics Boston Workshop
2019-03-21 08:30 - 14:00 (America/New_York) | Boston University School of Law, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Speakers include Kevin Outterson, CARB-X Executive Director.
The Longitude Prize is an international challenge prize competition that will ultimately select one point-of-care diagnostic product to receive a grand payout of 8 million British Pounds ($9.1 million). The winner will have proven that their test can significantly reduce misuse or overuse of antibiotics by creating an affordable, accurate and rapid point-of-care diagnostic test. This test must be practical to use in the North America and Europe as well as low and middle-income countries (LMICs). There are currently 83 teams competing for the Prize from 14 countries with a broad mix of entries from industry and academia. The Prize Rules can be found here.
The purpose of this workshop is to give existing competitors and those interested in competing more information regarding the Longitude Prize competition to help steer projects toward a winning configuration, hear from experts on test needs in the United Kingdom (National Health Service) and lower and middle-income contexts (LMICs), and to provide a chance for test developers to engage with Longitude judges and the Nesta Team.
The Longitude Prize is hosted and managed by the Challenge Prize Centre at Nesta, the Innovation Foundation based in London.
Please RSVP to Ruth Neale at ruth.neale@nesta.org.uk by Friday March 8, 2019 if you plan to attend the workshop.

Inaugural Bacteriophage Therapy Summit
2019-03-25 - 2019-03-27 | Revere Boston Common, 200 Stuart St., Boston, MA, 02116, United States
Speakers include Karen Gallant, CARB-X Global Project Director.
The 1st Bacteriophage Therapy Summit is the only meeting uniting large pharma, biotech companies, research institutions and technology experts to harness bacteriophage science and accelerate the clinical development of effective phage therapy. Join the leaders in phage therapy product development as they discuss the latest data-driven case studies and forge collaborations you need to unlock the full potential of bacteriophage therapeutics.
See the full agenda and speaker list here.
CARB-X subscribers qualify for an exclusive 10% discount with VIP Code 12259CARBX.

The Economist Antimicrobial Resistance Summit - Preventing an Antibiotic Apocalypse
2019-03-26 | BMA House Conference and Events Venue, Tavistock Square, Bloomsbury, London, WC1H 9JP, United Kingdom
Speakers include Kevin Outterson, CARB-X Executive Director.
Join 120+ health policy leaders, academics and other experts across the industry for a frank discussion to catalyse progress in bringing AMR under control, before it is too late. A series of expert panel discussions will dig into the topics that matter the most, using the convening power of The Economist brand to get the right people working together.

GARDP Webinar - Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
2019-03-28 17:00 - 18:30 (Europe/Paris) | Webinar
The overall goal of this series of webinars is to provide, for the non-clinical developer, an understanding of the risks of development for various kinds of antibacterial products. In this third webinar, we will discuss the development of antibacterial drug enhancer combinations and non-traditional products.
The webinar will be held from 5:00 pm – 6:30 pm CET / 12:00 pm – 13:30 pm EDT.
The presentations will be followed by a Q&A session.
